Study ID,Study,Experiment Name,Experiment Notes,Strain Ont ID,Strain,Sex,Age,# of Animals,Sample Notes,Clinical Measurement Ont ID,Phenotype,Formula,Clinical Measurement Notes,Average Type,Value,Units,SEM,SD,Method Ont ID,Method,Method Site,Method Duration,Method Notes,Post Insult Type,Post Insult Time Value,Post Insult Time Unit,Conditions,Record ID,Condition 1,Condition 2,Condition 3a,Condition 3b 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",erythrocyte quantity,,RS:0000742,WKY,male,0 days,11,,CMO:0000037,hematocrit,,,,45.2,%,1.4,4.6433,MMO:0000214,hematocrit analysis,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then vehicle control condition,99975,unilateral nephrectomy (for 28 days),vehicle control condition,, 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",erythrocyte quantity,,RS:0000742,WKY,male,0 days,17,,CMO:0000037,hematocrit,,,,44.8,%,0.6,2.4739,MMO:0000214,hematocrit analysis,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition,99976,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,vehicle control condition, 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",erythrocyte quantity,,RS:0000742,WKY,male,0 days,17,,CMO:0000037,hematocrit,,,,45.6,%,0.3,1.2369,MMO:0000214,hematocrit analysis,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 154 days),99977,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,bosentan (100 mg/kg/d) (for 154 days), 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",erythrocyte quantity,,RS:0000742,WKY,male,0 days,16,,CMO:0000037,hematocrit,,,,45.8,%,0.5,2.0,MMO:0000214,hematocrit analysis,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 154 days),99978,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,enalapril (10 mg/kg/d) (for 154 days), 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",erythrocyte quantity,,RS:0000742,WKY,male,0 days,16,,CMO:0000037,hematocrit,,,,44.5,%,0.6,2.4,MMO:0000214,hematocrit analysis,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 154 days) and bosentan (100 mg/kg/d) (for 154 days),99979,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,enalapril (10 mg/kg/d) (for 154 days),bosentan (100 mg/kg/d) (for 154 days) 2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",erythrocyte quantity,,RS:0000742,WKY,male,0 days,9,,CMO:0000037,hematocrit,,,,41,%,1.0,3.0,MMO:0000214,hematocrit analysis,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100436,0.9% sodium chloride solution (3 ml) ,,, 2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",erythrocyte quantity,,RS:0000742,WKY,male,0 days,7,,CMO:0000037,hematocrit,,,,39,%,1.0,2.6458,MMO:0000214,hematocrit analysis,,0.0,,PA IV 50mg/kg,23,days,puromycin aminonucleoside (50 mg/kg) ,100437,puromycin aminonucleoside (50 mg/kg) ,,, 2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",erythrocyte quantity,,RS:0000742,WKY,male,0 days,5,,CMO:0000037,hematocrit,,,,35,%,1.0,2.2361,MMO:0000214,hematocrit analysis,,0.0,,PA IV 50mg/kg,23,days,controlled enalapril content drinking water (50 mg/l) (for 30 days) then puromycin aminonucleoside (50 mg/kg) ,100438,controlled enalapril content drinking water (50 mg/l) (for 30 days),puromycin aminonucleoside (50 mg/kg) ,, 2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",erythrocyte quantity,,RS:0000742,WKY,male,0 days,8,,CMO:0000037,hematocrit,,,,45,%,1.0,2.8284,MMO:0000214,hematocrit analysis,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100439,0.9% sodium chloride solution (3 ml) ,,, 2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",erythrocyte quantity,,RS:0000742,WKY,male,0 days,9,,CMO:0000037,hematocrit,,,,43,%,1.0,3.0,MMO:0000214,hematocrit analysis,,0.0,,PA IV 50mg/kg,,,puromycin aminonucleoside (50 mg/kg) ,100440,puromycin aminonucleoside (50 mg/kg) ,,, 2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",erythrocyte quantity,,RS:0000742,WKY,male,0 days,8,,CMO:0000037,hematocrit,,,,43,%,1.0,2.8284,MMO:0000214,hematocrit analysis,,0.0,,PA IV 50mg/kg,,,controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days) then puromycin aminonucleoside (50 mg/kg) ,100441,controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days),puromycin aminonucleoside (50 mg/kg) ,, 2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",erythrocyte quantity,,RS:0000742,WKY,male,0 days,9,,CMO:0000037,hematocrit,,,,44,%,1.0,3.0,MMO:0000214,hematocrit analysis,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100442,0.9% sodium chloride solution (3 ml) ,,, 2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",erythrocyte quantity,,RS:0000742,WKY,male,0 days,8,,CMO:0000037,hematocrit,,,,44,%,1.0,2.8284,MMO:0000214,hematocrit analysis,,0.0,,PA IV 50mg/kg,490,days,puromycin aminonucleoside (50 mg/kg) ,100443,puromycin aminonucleoside (50 mg/kg) ,,, 2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",erythrocyte quantity,,RS:0000742,WKY,male,0 days,9,,CMO:0000037,hematocrit,,,,42,%,1.0,3.0,MMO:0000214,hematocrit analysis,,0.0,,PA IV 50mg/kg,490,days,controlled enalapril content drinking water (50 mg/l) (for 497 days) then puromycin aminonucleoside (50 mg/kg) ,100444,controlled enalapril content drinking water (50 mg/l) (for 497 days),puromycin aminonucleoside (50 mg/kg) ,,